Cytokinetics Inc (CYTK) Company Profile & Statistics

Cytokinetics Inc
CYTK
(Nasdaq - US)
Closed
47.65
-2.21 (-4.43%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
50.05
High
50.27
Low
47.61

About Cytokinetics Inc

CEO

ROBERT I. BLUM

Headquarters

350 oyster point boulevard

south san francisco, ca 94080, united states

Auditor

Ernst & Young LLP

Employees

423

Share Holders

Website

www.cytokinetics.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.

Cytokinetics Inc Statistics

Valuation Measures

Market Capitalization ²	5.62B
Enterprise Value	6.23B
Enterprise Value/EBITDA (ttm)	-12.19
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	N/A
Price to Sales (ttm)	1.87K
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-17906.25%
Profit Margin (ttm)	-29166.15%
Return on Equity (ttm)	N/A
Return on Invested Capital (ttm)	-170.90%
Return on Assets (ttm)	-50.21%

Income Statement

Revenue (ttm)	3.22M
Revenue Per Share (ttm)	0.03
Gross Profit (ttm)	3.22M
EBITDA (ttm)³	-511.14M
Net Income Avi to Common (ttm)	-576.40M
Diluted EPS (ttm)	-5.38

Share Statistics

Beta (5Y Monthly)	0.78
52-Week Change	47.48%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	118.01M
Dividend Yield	0.00%
Float ⁴	114.00M
% Held by Insiders	3.40%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	1.01B
Total Cash Per Share (mrq)	8.57
Total Debt (mrq)	656.02M
Total Debt/Equity (mrq)	-4715.82%
Current Ratio (mrq)	9.28%
Quick Ratio (mrq)	9.28%
Book Value Per Share (mrq)	-0.12

Cash Flow

Operating Cash Flow Per Share (ytd)	-2.81
Free Cash Flow (ytd)	-332.94M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Cytokinetics Inc

Trade With A Regulated Broker